Press Release
Jun 03, 2021
Chris Martin | IASLC Media Contact | cmartin@davidjamesgroup.com
June 3, 2021 (Denver) — The International Association for the Study of Lung Cancer announced today that its Chief Executive Officer, Dave Mesko, MBA will leave the organization in August to pursue other opportunities.
“Under Dave’s leadership, the IASLC has successfully navigated the challenges facing the global lung cancer community due to COVID-19 over the past year,” said Tetsuya Mitsudomi, MD, IASLC President. “The Association’s solid foundation and efficient management have resulted in strong financial performance and a positive outlook for 2021. We are grateful for the capable leadership and business acumen that Dave has brought to the IASLC over the past three years.”
The IASLC has achieved much success due to Mesko’s expertise in financial management, operations, governance, and nonprofit management. During his tenure, Mesko has been responsible for focusing on the member experience, diversifying programming, strengthening the IASLC’s financial position, and modernizing operational efficiencies and long-range planning.
He has also led efforts to increase educational opportunities for members and to enhance and expand relevant scientific initiatives, including the Lung Ambition Alliance, the IASLC Lung Cancer News, and the launch of JTO Clinical and Research Reports. Mesko led the organization to achieve significant accomplishments including the increase of the Journal of Thoracic Oncology Impact Factor to 13.357, the highest annual member enrollment, and record attendance at the 2019 World Conference on Lung Cancer. He has also established a highly talented, experienced team and a cohesive, collegial culture that has been instrumental in positioning the IASLC for future growth.
“The IASLC extends its sincere thanks to Dave Mesko for his transformational leadership over the past several years,” Mitsudomi continued. “The IASLC will engage an executive search firm to identify the Association’s next CEO, who will continue to advance the IASLC’s mission and commitment to conquering thoracic cancers worldwide.”